Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL | Zendy

Jing Pan | Zendy; Shiyu Zuo | Zendy; Biping Deng | Zendy; Xiuwen Xu | Zendy; Chuo Li | Zendy; Qinlong Zheng | Zendy; Zhuojun Ling | Zendy; Weiliang Song | Zendy; Jinlong Xu | Zendy; Jiajia Duan | Zendy; Zelin Wang | Zendy; Xinjian Yu | Zendy; Alex H. Chang | Zendy; Xiaoming Feng | Zendy; Chunrong Tong | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL

Author(s) -

Jing Pan,

Shiyu Zuo,

Biping Deng,

Xiuwen Xu,

Chuo Li,

Qinlong Zheng,

Zhuojun Ling,

Weiliang Song,

Jinlong Xu,

Jiajia Duan,

Zelin Wang,

Xinjian Yu,

Alex H. Chang,

Xiaoming Feng,

Chunrong Tong

Publication year - 2019

Publication title -

blood

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.515

H-Index - 465

eISSN - 1528-0020

pISSN - 0006-4971

DOI - 10.1182/blood.2019003293

Subject(s) - chimeric antigen receptor , cd19 , medicine , refractory (planetary science) , cd22 , oncology , immunology , antigen , pediatrics , immunotherapy , biology , cancer , astrobiology

Pan and colleagues report one of the first prospective evaluations of planned sequential chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and then CD22 in a phase 1 trial, indicating acceptable toxicity and encouraging durable efficacy in pediatric patients with relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research